If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
224
results.
Updated on
15/10/2025 [07:00:00]
Results 175 to 200 of 224
Absstract of: CN120225501A
The present invention provides an ionizable lipid of formula (I) or a pharmaceutically acceptable salt thereof or a stereoisomer of any of them; a lipid nanoparticle comprising the ionizable lipid (in particular as an encapsulant), optionally comprising a pharmaceutically active agent; and a pharmaceutical composition comprising the lipid nanoparticles. The present invention also provides a lipid nanoparticle for a drug or a pharmaceutical composition comprising the same, and a use of the lipid nanoparticle as an encapsulant. # imgabs0 #
Absstract of: CN120051455A
Novel sulfur-containing lipids and nanoparticles containing the lipids and cargo molecules, such as nucleic acids, methods of formulating the lipids with nucleic acids to produce lipid nanoparticles, and chemical pathways for preparing the lipids, are provided. The lipid may have a structure of Formula A as defined herein. # imgabs0 #
Absstract of: CN120239748A
The present invention encompasses systems, kits, and compositions comprising two RNA molecules wherein a first RNA molecule comprises an open reading frame encoding a functional RNA dependent RNA polymerase (replicase), and wherein a second RNA molecule is a replicable RNA molecule comprising at least one miRNA sequence that, when present in a cell, is capable of being cleaved from the second replicable RNA, and wherein the second RNA molecule is a replicable RNA molecule that comprises at least one miRNA sequence that, when present in the cell, is capable of being cleaved from the second replicable RNA. The first RNA molecule is capable of replication and is capable of modulating gene expression in a cell, and the replicable RNA molecule is capable of trans-replication by a replicase encoded by the first RNA molecule. The invention also encompasses methods of treating or preventing cancer or infections or other diseases and disorders with such systems and compositions, and the use of such systems and compositions in such methods of treatment and prevention.
Absstract of: WO2024054855A1
The present disclosure relates to a combination therapy comprising an anti-VEGF antibody, a nanoparticle formulated plasmid comprising an IL-12 coding nucleic acid, and, optionally, at least one adjunctive chemotherapeutic drug, and methods of treatment using such combination therapies and/or compositions.
Absstract of: AU2023342067A1
Aqueous partitioning peptide capsules for delivery of active agents. The capsules comprise a membrane having an exterior surface and defining a liquid-receiving interior space configured to encapsulate water-soluble active agents therein. The capsule membrane consists of a plurality of linear peptides, each peptide comprising a hydrophobic core of between 4 and 12 hydrophobic amino acids flanked by N- and C-terminal hydrophilic segments each comprising between 3 to 4 hydrophilic amino acids. Methods of making peptide capsules and methods of using the peptide capsules to deliver active agents encapsulated therein or attached thereto to a variety of organisms is described.
Absstract of: US2025243254A1
IL-2 variant polypeptides and compositions comprising one or more IL-2 variant polypeptides, e.g., fusion polypeptides, having reduced affinity to IL-2Rα and IL-2Rβ are disclosed, as well as method for their use, e.g., in treatments involving cancer vaccines, TCR-T cell therapy and CAR-T cell therapy. Such polypeptides do not systemically activate multiple immune cell subsets, as native IL-2 delivered in high doses would, but rather predominantly activate only T cells whose T cell receptors (TCRs) are engaged with a peptide-MHC complex (pMHC) presented by an antigen presenting cell, which can thus provide a useful therapeutic index for pharmaceutical compositions comprising such polypeptides.
Absstract of: CN120390657A
The present invention relates to compositions for efficient delivery of gene editing agents to target cells, and methods of using the same to treat diseases or conditions.
Absstract of: AU2023385865A1
Disclosed herein are dense nanolipid fluid (DNLF) dispersions comprising desirable characteristics for incorporating bioactive agents such as peptides into lipid phase of the dispersion for biodelivery of the agents for their typical purpose. Continuous methods for preparing the DNLF dispersions are also disclosed herein to include formation of a crude mill base and passing the base through a twin screw extruder. Dispersions disclosed herein can express a particle size of less than 150 nm under stable storage conditions, while forming lamellar structures after exposure to heat and/or evaporation of the aqueous components of the dispersion.
Absstract of: CN120359038A
The present disclosure provides inhibitory nucleic acids, compositions comprising the inhibitory nucleic acids, and methods of using the inhibitory nucleic acids to treat various diseases.
Absstract of: EP4624460A1
Provided in the present invention are an ionizable lipid, and a drug delivery system containing the ionizable lipid. Specifically, provided in the present invention is an ionizable lipid having the structure of formula (I), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof. A lipid nanoparticle constructed by means of using the ionizable lipid can realize safe and efficient delivery of nucleic acid drugs, small-molecule drugs, peptide drugs and protein drugs.
Absstract of: EP4624451A1
The present invention belongs to the field of biomedicine, which discloses a class of lipid compounds containing carbamate bond and applications thereof. The lipid compounds have the following structures:wherein the definitions of the various groups are described in the specification. The lipid nanoparticulate carriers prepared from the compounds described in the present invention exhibit excellent biocompatibility and safety as well as unexpected improvements in transfection efficiency, making them suitable for biomedical industrialization.
Absstract of: WO2024108303A1
Lymphoid leukemia such as acute lymphoblastic leukemia (ALL) represents a devastating disease especially when it occurs in adults. While dose-intensification strategies have led to a significant improvement in outcomes for pediatric patients, prognosis for the elderly remains very poor, with only 30-40% of adult patients with ALL achieving long-term remission. Novel tumor-specific antigens (TSAs) shared by a large proportion of lymphoid leukemia cells are described herein. Most of the TSAs described herein derives from aberrantly expressed unmutated genomic sequences, such as intronic and intergenic sequences, which are not expressed in normal tissues. Nucleic acids, compositions, cells and vaccines derived from these TSAs are described. The use of the TSAs, nucleic acids, compositions, cells and vaccines for the treatment of leukemia such as lymphoid leukemia is also described.
Absstract of: WO2024102746A1
Methods are described for treating neurotrophic keratitis in a subject by administering an agent that inhibits fidgetin-like 2 activity, such as by using an RNA interference agent, e.g., siRNA.
Absstract of: MX2025011000A
The present disclosure provides a method of treating or ameliorating an operative complication of a cataract surgery. The method comprises administering nanoparticles of clobetasol propionate to a subject in need thereof.
Absstract of: MX2025010536A
The present invention provides novel ionizable lipids and novel lipid nanoparticles comprising messenger RNA (mRNA) useful for the delivery of nucleic acids, related pharmaceutical compositions or vaccines as defined herein for use in human or veterinary medicine, in particular for use in the treatment and/or prophylaxis of cancer diseases.
Absstract of: GB2639579A
An antimicrobial composition comprising an antimicrobial compound and a population of metal nanoparticles is provided. The antimicrobial compound is preferably an antibiotic. The metal nanoparticle may comprise silver and/or copper and may also comprise a polymer coating such as poly(N-vinylpyrrolidone). The antimicrobial composition wherein the population of silver nanoparticles is formed by (a) mixing a first aqueous alkaline solution with an aqueous polymer solution to form an aqueous polymer solution; and (b) mixing the aqueous alkaline polymer solution with an aqueous solution of a metal salt to form a solution of polymer-coated metal nanoparticles is provided. A coating or treatment for a surface or substrate comprising the antimicrobial composition is provided. A medical device comprising the coating or treatment is provided. The medical device may be a wound care dressing or a bandage. A silver nanoparticle coated with poly(N-vinylpyrrolidone) is exemplified. Combinations of the PVP-coated silver nanoparticles (AgNP) and various antibiotics were tested. Compositions comprising silver nanoparticles and aminoglycosides, such as kanamycin and gentamicin, were particularly effective. A combination of silver nanoparticles and ebselen was also particularly effective against E. coli and S. aureus.
Absstract of: CN120265279A
The present disclosure provides stable dry powder messenger RNA formulations for therapeutic use and methods of making and using the same.
Absstract of: MX2025008776A
A composition for treating hyperprocalcitonemia is described. The composition comprises a lipophilic or hydrophobic component, an amphiphilic emulsifier, a polar liquid carrier, and with or without one or more electrolytes, where the amphiphilic emulsifier forms micelles having a lipophilic or hydrophobic core comprising the lipophilic or hydrophobic component in the polar liquid carrier, and /or liposomes organized as a lipid bilayer and/or other particle configurations.
Absstract of: US2025129135A1
The present application relates to the pharmaceutical and biological fields, particularly relates to a polypeptide compound of general formula (I) with triple agonist activity on glucagon like peptide-1 receptor (GLP-1 R), glucose-dependent insulinotropic polypeptide receptor (GIP R), and glucagon receptor (GCG R), and use thereof in the treatment of metabolic syndrome.
Absstract of: EP4624462A2
The present disclosure provides a C6'-substituted locked nucleic acid-modified cap analog and a use thereof, wherein the cap analog improves the stability of mRNA and/or the translation efficiency of mRNA.
Absstract of: AU2024214423A1
Provided are ionizable cationic lipids and lipid nanoparticles for the delivery of nucleic acids to cells (e.g., HSC), and methods of making and using such lipids and targeted lipid. nanoparticles.
Absstract of: KR20250142178A
본 발명은 활성성분을 포함하는 균질하고 견고한 폴리머 복합체 나노입자(Polymer Complexes Nanoparticles, PMNP)와 자가유화 용액(Self-emulsifying solution, SES)로부터 자가유화 나노입자(Self-emulsifying nanoparticle, SENP) 및 비침습적 자가유화 나노입자 운반시스템(Self-emulsifying nanoparticle delivery system, SENPDS)을 제안하였다. 본 발명의 상기 SENPDS는 3중 다층 구조체로 생체 내에서 견고한 PMNP 함유 오일방울로 전환하여 자가소수성 반전 및 자가전하 반전을 하여 기존 SNEDDS(Self-nanoemulsifying drug delivery system)와 다른 생체장벽 회피 전략으로 향상된 생체이용률을 확인하였다. 본 발명은 SENP, SENPDS 및 이들의 제조 방법에 관한 것이다.
Absstract of: WO2025198324A1
The present invention relates to a polymer self-assembly nanocarrier and a method of preparing same, the nanocarrier binding a peptide that targets a specific cell and, simultaneously, carrying an active ingredient that has been verified. The present invention can exhibit various effects such as a moisturizing effect, an increase in filaggrin production, whitening, skin barrier reinforcement and the like by selectively and efficiently delivering a drug through a targeting peptide, can be applied to skin diseases such as atopy or psoriasis, and is expected to enable the maximum effect of an active substance in the pharmaceutical and cosmetic fields to be obtained.
Nº publicación: KR20250142185A 30/09/2025
Applicant:
김성천
Absstract of: KR20250142185A
본 발명은 활성성분을 포집한 나노입자(Nanoparticles, NP)와 자가유화 용액(Self-emulsifying solution, SES)으로부터 제조된 자가유화 나노입자(Self-emulsifying nanoparticle, SENP) 및 자가유화 나노입자 운반시스템(Self-emulsifying nanoparticle delivery system, SENPDS)을 제공한다. 경구 투여된 SENPDS는 위장관에서 수성 매체에 희석되면서 형성되는 NP 함유 지질방울은 전신 순환계에 유입되고 체류하면서 활성성분을 지속 방출할 수 있다. 이 과정에서 상기 온전한 NP 함유 지질방울은 자가소수성 반전 및 자가전하 반전을 포함하는 생체장벽 회피 전략으로 활성성분의 생체이용률이 향상됨을 확인하였다. 따라서, 본 발명의 SENPDS는 생체이용률이 향상된 의약품, 건강기능식품 및 화장품을 제공할 수 있다.
BOPI
Electronic site
